why gad-free will be adopted rapidly in the US at least15 Nov 2020 17:51
"Gadolinium-based contrast agents (GBCAs) are used over 10 million times worldwide each year in magnetic resonance imaging (MRI) scans to diagnose and characterize disease states affecting the central nervous system ...
In 2006 an association was established between GBCAs and a rare but devastating, and sometimes fatal, fibrosing disorder termed nephrogenic systemic fibrosis (NSF) in patients with impaired kidney function. ...
Deposition of Gd in the brain and other organs, e.g. bone, has been observed with all GBCAs regardless of kidney function ...
The FDA assigned a new class warning to all GBCAs advising physicians to carefully consider the retention characteristics of a GBCA before prescribing contrast enhanced examinations. ...
All intravenous contrast agents approved for use and that are commercially available contain Gd.
from Gale & Caravan 2018, "Gadolinium-free contrast agents for magnetic resonance imaging of the central nervous system" DOI: 10.1021/acschemneuro.8b00044 , https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994911/